Aerocrine AB responds to recent speculation in the market
SOLNA, Sweden – Aerocrine AB (OMX Nordic Exchange: AERO) responds to recent speculation in the market.
Aerocrine has noted recent speculation in the markets. The Board of Aerocrine confirms that it is in preliminary discussions with a third party concerning a public offer for Aerocrine. There can be no certainty that an offer will be made, nor as to the terms of any such offer. A further announcement will be made in due course.
For more information about Aerocrine:
Scott Myers, Chief Executive Officer, Aerocrine AB, Phone: +1 970 368 0336
Marshall Woodworth, Chief Financial Officer, Aerocrine AB: +1 919 749 8748 or +46 709 695 219
Mats Carlson, Vice President of Global Operations, Aerocrine AB: +46 70 534 89 89
Or visit www.aerocrine.com
Aerocrine AB is a medical products company focused on the improved management and care of patients with inflammatory airway diseases. As the pioneer and leader in technology to monitor and manage airway inflammation, Aerocrine markets NIOX MINO® and NIOX VERO®. Both products enable fast and reliable management of airway inflammation and may therefore play a critical role in more effective diagnosis, treatment and follow-up of patients with inflammatory airway diseases such as asthma. Aerocrine is based in Sweden with subsidiaries in the U.S., Germany, Switzerland and the U.K. Aerocrine shares were listed on the Stockholm Stock Exchange in 2007.
Aerocrine is required to disclose the information provided herein pursuant to the Swedish Securities Markets Act. The information was submitted for publication at 08:00 p.m. on April 27, 2015.